BMS' Opdivo Gets CHMP Backing For Expanded European Label
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb Co's lead in the PD-1 inhibitor space was reinforced by news the European Medicines Agency's top advisory committee thinks Opdivo (nivolumab) should have its label expanded to include previously treated advanced renal cell carcinoma in adults as well as previously treated metastatic non-squamous non-small cell lung cancer, regardless of PD-L1 expression.